Patent application number | Description | Published |
20100215650 | METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists. | 08-26-2010 |
20100226930 | Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders. | 09-09-2010 |
20100272736 | COMBINATION ANTIBIOTIC AND ANTIBODY THERAPY FOR THE TREATMENT OF PSEUDOMONAS AERUGINOSA INFECTION - The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with | 10-28-2010 |
20110243934 | EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of multiple myeloma. | 10-06-2011 |
20110245100 | GENERATION OF ANTIBODIES TO AN EPITOPE OF INTEREST - The invention provides methods of obtaining antibodies to an epitope of interest based on an anti-hapten focused library. | 10-06-2011 |
20110318304 | DETECTION OF EPHA3 AS A MARKER OF THE PRESENCE OF A SOLID TUMOR - The invention provides methods and compositions for detecting non-hematopoietic, non-tumor EphA3-expressing cells in cancer patients and for monitoring the prognosis of patients using EphA3. | 12-29-2011 |
20120009191 | METHODS OF TREATING BONE-LOSS DISORDERS USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists. | 01-12-2012 |
20130039907 | METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW - The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders. | 02-14-2013 |
20130064826 | ANTI-EMR1 ANTIBODIES - The invention provides anti-EMR1 antibodies and methods of using such antibodies to treat EMR1-related diseases. | 03-14-2013 |
20130156759 | METHODS OF TREATING DEMENTIA USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists. | 06-20-2013 |
20140370010 | TREATMENT OF LEUKEMIAS AND CHRONIC MYELOPROLIFERATIVE DISEASES WITH ANTIBODIES TO EPHA3 - The invention provides methods and compositions comprising anti-EphA3 antibodies for the treatment of myeloproliferative disorders. | 12-18-2014 |
Patent application number | Description | Published |
20090017532 | Vector - A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor. | 01-15-2009 |
20090111144 | Transactivation system for mammalian cells - The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein. | 04-30-2009 |
20100040539 | Vector System - The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications. | 02-18-2010 |
20110052577 | Antibodies - The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications. | 03-03-2011 |
20110065173 | Vector - A vector comprising a nucleotide sequence of interest (“NOI”) encoding a product of interest (“POI”) is described. The NOI and/or the POI is capable of recognizing a tumor, such that in use the vector is capable of delivering the NOI and/or the POI to the tumor. | 03-17-2011 |